Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Bikramjit Chopra"'
Autor:
Heide Stirnadel-Farrant, Mahesh Kudari, Nadia Garman, Jessica Imrie, Bikramjit Chopra, Stefania Giannelli, Michela Gabaldo, Ambra Corti, Stefano Zancan, Alessandro Aiuti, Maria Pia Cicalese, Rohit Batta, Jonathan Appleby, Mario Davinelli, Pauline Ng
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-10 (2018)
Abstract Background Strimvelis (autologous CD34+ cells transduced to express adenosine deaminase [ADA]) is the first ex vivo stem cell gene therapy approved by the European Medicines Agency (EMA), indicated as a single treatment for patients with ADA
Externí odkaz:
https://doaj.org/article/a8893f1115da49d982593a6f5bd7315f
Autor:
Hang Quach, Mercedes Gironella, Cindy Lee, Rakesh Popat, Paul Cannell, Ravi S. Kasinathan, Bikramjit Chopra, Rachel Rogers, Geraldine Ferron-Brady, Seema Shafi-Harji, Nashita Patel, Joanna Opalinska, Ira Gupta, Bradley Augustson
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S423-S424
Autor:
Hang Quach, Mercedes Gironella, Cindy Lee, Rakesh Popat, Paul Cannell, Ravi S. Kasinathan, Bikramjit Chopra, Rachel Rogers, Geraldine Ferron-Brady, Seema Shafi-Harji, Nashita Patel, Joanna Opalinska, Ira Gupta, Bradley Augustson
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S183
Autor:
Hang Quach, Mercedes Gironella, Cindy Lee, Rakesh Popat, Paul Cannell, Ravi S. Kasinathan, Bikramjit Chopra, Rachel Rogers, Geraldine Ferron-Brady, Seema Shafi-Harji, Nashita Patel, Joanna Opalinska, Ira Gupta, Bradley Augustson
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S116
Autor:
Hang Quach, Mercedes Gironella, Cindy Lee, Rakesh Popat, Paul Cannell, Ravi Kasinathan, Bikramjit Chopra, Rachel Rogers, Geraldine Ferron-Brady, Seema Shafi-Harji, Nashita Patel, Joanna Opalinska, Ira V. Gupta, Bradley Augustson
Publikováno v:
Journal of Clinical Oncology. 40:8017-8017
8017 Background: Belantamab mafodotin (belamaf; BLENREP) is a B-cell maturation antigen-targeting antibody–drug conjugate approved for patients (pts) with RRMM as monotherapy at 2.5 mg/kg Q3W. Preclinical data demonstrate synergy between belamaf an
Autor:
Ryan Ramaekers, Mala K. Talekar, Keith Stockerl-Goldstein, Bradley Augustson, Bikramjit Chopra, Rocio Montes de Oca, Deborah A. Smith, Rafat Abonour, Geraldine Ferron-Brady, Andrew Spencer, Jacqueline Davidge, Maria-Victoria Mateos, Amit Khot, Ajay K. Nooka, Brandon E. Kremer, Cindy Lee, Rachel Rogers, Adam Forbes, Rakesh Popat, Ira Gupta, Anne Yeakey, Hang Quach
Publikováno v:
Blood. 136:19-20
Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, demonstrated deep and durable responses with a manageable safety profile in patients with heavily pretreated RRMM (median 7 lines of prior
Autor:
Ira Gupta, Suzanne Trudel, Geraldine Ferron-Brady, Brandon E. Kremer, Randy Davis, Laurie Eliason, Frank S. Wu, Nicole M. Lewis, Rocio Montes de Oca, Kalpana Bakshi, Bikramjit Chopra
Publikováno v:
Blood. 136:4-4
Introduction: Belantamab mafodotin (belamaf; GSK2857916) is a B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate. In the pivotal Phase II DREAMM-2 study, single-agent belamaf demonstrated deep and durable responses with a manageable s
Autor:
Ira Gupta, Geraldine Ferron-Brady, Rafat Abonour, Hang Quach, Maria-Victoria Mateos, Adam Forbes, Amit Khot, Mala K. Talekar, Alan Tan, Katarina Luptakova, Steve Frey, Bikramjit Chopra, Rakesh Popat, Keith Stockerl-Goldstein, Jacqueline Davidge, Anne Yeakey, Ajay K. Nooka, Rachel Rogers
Publikováno v:
Journal of Clinical Oncology. 38:8502-8502
8502 Background: Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated RRMM refractory to an immunomodulatory agent, a proteasome in
Autor:
Bradley Augustson, Allie Moore, Hang Quach, Jiangxiu Zhou, Veronique Bragulat, Luciano J. Costa, Bikramjit Chopra, Joanna Opalinska, Mala K. Talekar, Keith Stockerl-Goldstein, Sophia Hudson, Geraldine Ferron-Brady
Publikováno v:
Journal of Clinical Oncology. 37:TPS8053-TPS8053
TPS8053 Background: B-cell maturation antigen (BCMA) is a validated therapeutic target in Multiple Myeloma (MM). GSK2857916 is a humanized (IgG1) anti-BCMA monoclonal antibody conjugated to monomethyl auristatin-F via protease resistant maleimidocapr
Autor:
Bikramjit Chopra, Jonathan M. Beckel, Ann T. Hanna-Mitchell, Stacey Barrick, Joel R Gever, Lori A. Birder, Anthony P.D.W. Ford
Publikováno v:
American Journal of Physiology-Renal Physiology. 294:F821-F829
The control and regulation of the lower urinary tract are partly mediated by purinergic signaling. This study investigated the distribution and function of P2Y receptors in the rat urinary bladder. Application of P2Y agonists to rat urothelial cells